GenMark Diagnostics, Inc (GNMK) SVP Sells $11,283.16 in Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Eric Stier sold 1,652 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $6.83, for a total transaction of $11,283.16. Following the transaction, the senior vice president now owns 240,102 shares of the company’s stock, valued at approximately $1,639,896.66. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Eric Stier also recently made the following trade(s):

  • On Monday, February 25th, Eric Stier sold 11,243 shares of GenMark Diagnostics stock. The stock was sold at an average price of $6.80, for a total transaction of $76,452.40.

Shares of NASDAQ:GNMK traded down $0.29 on Thursday, reaching $6.67. 6,612 shares of the company were exchanged, compared to its average volume of 288,738. The company has a quick ratio of 3.40, a current ratio of 3.93 and a debt-to-equity ratio of 1.96. GenMark Diagnostics, Inc has a 1-year low of $3.58 and a 1-year high of $8.81. The stock has a market cap of $398.63 million, a PE ratio of -7.26 and a beta of 1.55.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01). GenMark Diagnostics had a negative return on equity of 137.04% and a negative net margin of 71.40%. The company had revenue of $21.53 million for the quarter, compared to analyst estimates of $21.08 million. Equities analysts anticipate that GenMark Diagnostics, Inc will post -0.81 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Ameritas Investment Corp acquired a new stake in shares of GenMark Diagnostics during the 1st quarter worth about $43,000. FMR LLC boosted its stake in shares of GenMark Diagnostics by 0.9% during the 1st quarter. FMR LLC now owns 8,470,863 shares of the medical equipment provider’s stock worth $60,058,000 after purchasing an additional 77,571 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of GenMark Diagnostics by 9.7% during the 1st quarter. HighTower Advisors LLC now owns 2,540,041 shares of the medical equipment provider’s stock worth $18,009,000 after purchasing an additional 225,110 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of GenMark Diagnostics by 123.3% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,466 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 2,466 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of GenMark Diagnostics by 11.6% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 167,400 shares of the medical equipment provider’s stock worth $1,187,000 after purchasing an additional 17,400 shares during the last quarter. 91.76% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have commented on GNMK. BidaskClub upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, May 4th. Zacks Investment Research cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $9.67.

ILLEGAL ACTIVITY NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2019/05/23/genmark-diagnostics-inc-gnmk-svp-sells-11283-16-in-stock.html.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Further Reading: What is Put Option Volume?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.